Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates

Core Insights - Novavax reported earnings of 11 cents per share in Q4 2025, significantly beating the Zacks Consensus Estimate of a loss of 66 cents, and improved from a loss of 51 cents in the same quarter last year [1][8] - Quarterly revenues reached $147.1 million, representing a 67% year-over-year increase, surpassing the Zacks Consensus Estimate of $78.4 million [1][8] Financial Performance - The company recorded $39.2 million in product sales, a decrease of 34% year over year, which included approximately $20 million from COVID-19 vaccine sales and $19 million from Matrix-M supply sales [4] - Licensing, royalties, and other revenues totaled $108 million, with $98 million recognized under the licensing agreement with Sanofi, marking a 67% increase year over year [5][8] - For the full year 2025, Novavax generated revenues of $1.1 billion, up 65% year over year, and reported earnings of $2.58 per share compared to a loss of $1.23 in the previous year [11] Cost Management - Research and development (R&D) expenses were $75.9 million, down 27% year over year, aided by cost reduction efforts, excluding $28 million of R&D reimbursement from Sanofi [9] - Selling, general, and administrative (SG&A) expenses decreased by 56% year over year to $34.1 million, primarily due to the transition of commercial activities to Sanofi [9] Cash Position - As of December 31, 2025, Novavax had $751 million in cash and cash equivalents, a slight decrease from $778 million in the previous quarter [10] Future Guidance - For 2026, Novavax expects adjusted revenues between $230 million and $270 million, excluding amounts receivable from Sanofi [12] - The company anticipates combined R&D and SG&A expenses for 2026 to be in the range of $380 million to $420 million, excluding expected R&D reimbursements from Sanofi [13] Recent Developments - Novavax entered a non-exclusive license agreement with Pfizer, receiving an upfront payment of $30 million and potential milestone payments up to $500 million [14] - The company signed multiple material transfer agreements for its Matrix-M adjuvant and is advancing its preclinical pipeline, with plans to start clinical studies on new vaccine candidates as early as next year [15]